This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Junttila, T. T. Articles by Elenius, K. Search for Related Content PubMed PubMed Citation Articles by Junttila, T. T. Articles by Elenius, K.

Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms

Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients

Medicity Research Laboratories, and Department of Medical Biochemistry and Molecular Biology [T. T. J., K. E.], and Turku Graduate School of Biomedical Sciences [T. T. J.], University of Turku, FIN-20520 Turku; Departments of Surgery [M. L.], Pathology [K-O. S.], and Oncology [K. E.], Turku University Central Hospital, FIN-20520 Turku; Department of Biostatistics, University of Turku, FIN-20014 Turku [T. Va.]; and Laboratories of Cancer Genetics [T. Vi.] and Cancer Biology [J. I.], Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33101 Tampere, Finland

Purpose: The purpose of this research was to quantitatively analyze tumor-specific overexpression of all ErbB receptors and ErbB4 isoforms in transitional cell carcinoma (TCC) of the bladder.

Experimental Design: A real-time reverse transcription-PCR protocol was set up to simultaneously quantitate the mRNA levels of all four of the ErbB receptors and ErbB4 isoforms. Exon-intron structure of the ErbB4 gene was determined for ErbB4 isoform analysis. The assay was validated by analyzing: (a) defined ErbB cDNAs; (b) cell lines transfected with defined ErbB cDNAs; and (c) cancer cell lines with ErbB status controlled by Western blotting. ErbB mRNA expression was quantitated from 29 clinical samples representing TCC, interstitial cystitis, or histologically normal bladder. Cutoff expression levels predicting neoplasia at 95% probability were determined. ErbB expression and amplification was analyzed by immunohistochemistry and chromogenic in situ hybridization.

Results: Experiments with control cDNAs and cell lines demonstrated that the assay was both specific and sensitive, and that ErbB mRNA levels closely correlated with protein levels in cancer cell lines. Determination of cutoff expression levels indicated tumor-specific overexpression of ErbB2, ErbB3, and specific ErbB4 isoforms in a subset of TCC patients. Significant overexpression of ErbB mRNAs was also detected in cases without amplification of the respective gene or when the protein product was not localized at the cell membrane.

Conclusion: Bladder cancer patients with tumor-specific overexpression of ErbB receptors or their isoforms were identified. Real-time reverse transcription-PCR could be used for ErbB receptor status quantitation to produce prognostic and predictive information for cancer therapy.

This article has been cited by other articles:

				A. J. Law, J. E. Kleinman, D. R. Weinberger, and C. S. Weickert Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia Hum. Mol. Genet., January 15, 2007; 16(2): 129 - 141. [Abstract] [Full Text] [PDF]

				S. P. van der Woning, W. van Rotterdam, S. B. Nabuurs, H. Venselaar, S. Jacobs-Oomen, M. Wingens, G. Vriend, C. Stortelers, and E. J. J. van Zoelen Negative Constraints Underlie the ErbB Specificity of Epidermal Growth Factor-like Ligands J. Biol. Chem., December 29, 2006; 281(52): 40033 - 40040. [Abstract] [Full Text] [PDF]

				S. Semba, S.-Y. Han, H. R. Qin, K. A. McCorkell, D. Iliopoulos, Y. Pekarsky, T. Druck, F. Trapasso, C. M. Croce, and K. Huebner Biological Functions of Mammalian Nit1, the Counterpart of the Invertebrate NitFhit Rosetta Stone Protein, a Possible Tumor Suppressor J. Biol. Chem., September 22, 2006; 281(38): 28244 - 28253. [Abstract] [Full Text] [PDF]

				K. Erjala, M. Sundvall, T. T. Junttila, N. Zhang, M. Savisalo, P. Mali, J. Kulmala, J. Pulkkinen, R. Grenman, and K. Elenius Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells. Clin. Cancer Res., July 1, 2006; 12(13): 4103 - 4111. [Abstract] [Full Text] [PDF]

				J. A. Maatta, M. Sundvall, T. T. Junttila, L. Peri, V. J. O. Laine, J. Isola, M. Egeblad, and K. Elenius Proteolytic Cleavage and Phosphorylation of a Tumor-associated ErbB4 Isoform Promote Ligand-independent Survival and Cancer Cell Growth Mol. Biol. Cell, January 1, 2006; 17(1): 67 - 79. [Abstract] [Full Text] [PDF]

				R. R. Arasada and G. Carpenter Secretase-dependent Tyrosine Phosphorylation of Mdm2 by the ErbB-4 Intracellular Domain Fragment J. Biol. Chem., September 2, 2005; 280(35): 30783 - 30787. [Abstract] [Full Text] [PDF]

				A. Mialon, M. Sankinen, H. Soderstrom, T. T. Junttila, T. Holmstrom, R. Koivusalo, A. C. Papageorgiou, R. S. Johnson, S. Hietanen, K. Elenius, et al. DNA Topoisomerase I Is a Cofactor for c-Jun in the Regulation of Epidermal Growth Factor Receptor Expression and Cancer Cell Proliferation Mol. Cell. Biol., June 15, 2005; 25(12): 5040 - 5051. [Abstract] [Full Text] [PDF]

				T. T. Junttila, M. Sundvall, M. Lundin, J. Lundin, M. Tanner, P. Harkonen, H. Joensuu, J. Isola, and K. Elenius Cleavable ErbB4 Isoform in Estrogen Receptor-Regulated Growth of Breast Cancer Cells Cancer Res., February 15, 2005; 65(4): 1384 - 1393. [Abstract] [Full Text] [PDF]

				M. Tanner, M. Hollmen, T. T. Junttila, A. I. Kapanen, S. Tommola, Y. Soini, H. Helin, J. Salo, H. Joensuu, E. Sihvo, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II{alpha} gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann. Onc., February 1, 2005; 16(2): 273 - 278. [Abstract] [Full Text] [PDF]

				M. Tanner, A. I. Kapanen, T. Junttila, O. Raheem, S. Grenman, J. Elo, K. Elenius, and J. Isola Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer Mol. Cancer Ther., December 1, 2004; 3(12): 1585 - 1592. [Abstract] [Full Text] [PDF]